In a small study on nondialysis CKD patients, daily potassium intake was not associated with hyperkalemia (serum potassium level above 5 mEqL) in patients with chronic kidney disease.
In a Swiss study, patients aged 80 years or more were significantly less likely to die if they had a nephrology referral prior to initiating dialysis.
Patients with vs without anemia prior to starting hemodialysis (HD) were more likely to die despite achieving target hemoglobin levels at month 4 after HD initiation.
Type 2 diabetes is among the leading causes of end-stage renal disease (ESRD), but the estimated cumulative risk of ESRD at 20 years after diagnosis of type 2 diabetes is less than 1%.
Anemia is 66% and 84% more likely to develop among patients in the 3rd and 4th quartiles of serum fibroblast growth factor 23 level vs those in the 1st quartile.
Rates of hyperkalemia associated with receipt of renin-angiotensin-aldosterone system inhibitors vary by age and comorbidities.
Longitudinal study with preplanned serum potassium measurements may provide a more accurate estimate of the burden of hyperkalemia among CKD patients.
Patients in the highest quintile of urinary albumin excretion had a 4.5-fold increased risk of urothelial cell carcinoma vs those in quintiles 1-3.
The risk of chronic kidney disease among women who experience preeclampsia is particularly elevated within 5 years of delivery.
In a phase 2 trial that enrolled 31 patients with autosomal dominant polycystic kidney disease, treatment with bardoxolone resulted in a significant increase in kidney function.
Please login or register first to view this content.
